Ventyx Biosciences, Inc. (NASDAQ:VTYX) Expected to Post FY2024 Earnings of ($2.14) Per Share

Ventyx Biosciences, Inc. (NASDAQ:VTYX) – Stock analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for shares of Ventyx Biosciences in a note issued to investors on Tuesday, October 15th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($2.14) for the year, down from their prior forecast of ($2.13). HC Wainwright has a “Neutral” rating and a $6.00 price objective on the stock. The consensus estimate for Ventyx Biosciences’ current full-year earnings is ($2.14) per share. HC Wainwright also issued estimates for Ventyx Biosciences’ Q4 2024 earnings at ($0.59) EPS and FY2025 earnings at ($2.93) EPS.

A number of other equities analysts also recently commented on VTYX. Canaccord Genuity Group decreased their target price on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Wells Fargo & Company reduced their price objective on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Ventyx Biosciences has an average rating of “Moderate Buy” and an average price target of $8.29.

Ventyx Biosciences Stock Performance

NASDAQ VTYX opened at $2.57 on Thursday. Ventyx Biosciences has a one year low of $1.79 and a one year high of $19.04. The company has a 50-day simple moving average of $2.17 and a 200-day simple moving average of $3.12. The firm has a market capitalization of $181.62 million, a PE ratio of -0.92 and a beta of 0.36.

Ventyx Biosciences (NASDAQ:VTYX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.12.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in VTYX. Norden Group LLC bought a new stake in shares of Ventyx Biosciences during the first quarter valued at about $59,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Ventyx Biosciences during the 1st quarter worth about $72,000. SG Americas Securities LLC acquired a new stake in shares of Ventyx Biosciences in the 2nd quarter worth approximately $32,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Ventyx Biosciences by 41.1% in the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock valued at $56,000 after acquiring an additional 7,096 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Ventyx Biosciences during the second quarter valued at approximately $58,000. Institutional investors and hedge funds own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.